TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2677294

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 641180

Group type: EXPERIMENTAL
Intervention: Unilateral Right ECT (UR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral Left ECT (UL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 31153148

Group type: EXPERIMENTAL
Intervention: Gross-total resection
Number of subjects: 12931

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after subtotal resection
Number of subjects: 12931

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after gross-total resection
Number of subjects: 12931

Group type: COMPARATOR
Intervention: Gross-total resection plus radiotherapy
Number of subjects: 12931

Group type: COMPARATOR
Intervention: Adjuvant radiation after subtotal resection
Number of subjects: 12931
Study: 28062315

Group type: EXPERIMENTAL
Intervention: Three-step technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: WHO six-step technique
Number of subjects: 32
Study: 26238866

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Profile (MSIP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Quality of Life-54 items (MSQoL-54)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Fatigue Impact Scale-5 items (MFIS-5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leeds Multiple Sclerosis Quality of Life-8 items (LMSQoL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication and Adherence Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 0
Study: 22913797

Group type: COMPARATOR
Intervention: Myopic group (n = 58)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Hyperopic group (n = 62)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Emmetropic control group (n = 34)
Number of subjects: 154
Study: 19683703

Group type: EXPERIMENTAL
Intervention: Well-Being intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 227
Study: 16505505

Group type: EXPERIMENTAL
Intervention: Insulin glargine 10 units/day
Number of subjects: 217

Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 217
Study: 15497664

Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg capsules (Losefar 500 mg Capsules)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg/5 mL suspension (Losefar 250 mg/5 mL Granules oral suspension)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cefaclor (both formulations)
Number of subjects: 2
Study: 11266032

Group type: EXPERIMENTAL
Intervention: Parenteral vitamin B12 (3 injections of 1 mg at 4-week intervals)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (high doses of folic acid and replacement-dose oral vitamin B12)
Number of subjects: 14
Study: 9135187

Group type: EXPERIMENTAL
Intervention: Acceleromyography (TOF‐Guard)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mechanomyography (Grass FT03)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acceleromygraphy
Number of subjects: 15
Study: 8044004

Group type: COMPARATOR
Intervention: Controlled trials in JITWM
Number of subjects: 314

Group type: COMPARATOR
Intervention: Controlled trials in JTCM
Number of subjects: 314

Group type: COMPARATOR
Intervention: Controlled trials in JTM
Number of subjects: 314

Group type: COMPARATOR
Intervention: Randomized trials in JITWM
Number of subjects: 314

Group type: COMPARATOR
Intervention: Randomized trials in JTCM
Number of subjects: 314

Group type: COMPARATOR
Intervention: Randomized trials in JTM
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Quality ranking of clinical trials
Number of subjects: 314
Study: 3692076

Group type: EXPERIMENTAL
Intervention: Statistical analysis of ST-T isoarea maps using body surface maps (BSM) recorded from 140 thoracic leads.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Learning set analysis with 17 pts without VT and 9 pts with VT.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Test set analysis with 8 pts without VT and 4 pts with VT.
Number of subjects: 38
Study: 29303475

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (ACTIVE framework)
Number of subjects: 2802
Study: 27378326

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 26547682

Group type: EXPERIMENTAL
Intervention: Function Focused Care Intervention
Number of subjects: 25
Study: 22965772

Group type: COMPARATOR
Intervention: RT-only treatment group (11 solitary and 3 multiple tumors)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined treatment group (10 solitary and 4 multiple tumors, neo-adjuvant CTX followed by response-adapted RT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: RT-only treatment group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 28
Study: 20850812

Group type: EXPERIMENTAL
Intervention: Prazosin (0.025 mg/kg nightly for 1 week, then increased to 2 divided doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (nightly for 1 week, then increased to 2 divided doses)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 62
Study: 18413501

Group type: EXPERIMENTAL
Intervention: OPCABG
Number of subjects: 60

Group type: COMPARATOR
Intervention: ONCABG
Number of subjects: 60
Study: 16753082

Group type: EXPERIMENTAL
Intervention: Self-reported physical functioning
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lower levels of physical functioning
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Weaker psychological attributions
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Work disability benefits
Number of subjects: 127
Study: 12610251

Group type: EXPERIMENTAL
Intervention: Psychoeducational computer program accessible via Internet or touch-tone telephone
Number of subjects: 786

Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 786
Study: 12043712

Group type: EXPERIMENTAL
Intervention: Four- or eight-week intervention aimed at reducing sexual risk
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 9798830

Group type: EXPERIMENTAL
Intervention: Conservative treatment plus whirlpool (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conservative treatment only (Group A)
Number of subjects: 42
Study: 8033762

Group type: EXPERIMENTAL
Intervention: Increased methadone dose (50-80 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Decreased methadone dose (80-50 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Expired air carbon monoxide (CO) measurement
Number of subjects: 5
Study: 2500273

Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F (300 mg/kg body weight every 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard intramuscular injections (25 mg/kg body weight every week after a 4-week loading phase of 50 mg/kg/week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F (300 mg/kg body weight every 3 weeks after initial treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F
Number of subjects: 12
Study: 4881069

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suramin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mel W
Number of subjects: 0
Study: 30583852

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-Emotion Development (PCIT-ED)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 118
Study: 28160720

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 41
Study: 24548796

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 10
Study: 23959084

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PA)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 176
Study: 21327633

Group type: EXPERIMENTAL
Intervention: α‐tocopherol (400 IU per day for entire period of radiotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (6000 cGY in five fractions per week for a period of six weeks)
Number of subjects: 0
Study: 19574612

Group type: EXPERIMENTAL
Intervention: Antioxidant nutrient cocktail
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17342169

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of clonidine and modafinil
Number of subjects: 16
Study: 15538264

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (3 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral sildenafil (50 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 34
Study: 11340689

Group type: EXPERIMENTAL
Intervention: Budesonide (64 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Xylometazoline (140 micrograms)
Number of subjects: 6
Study: 9481967

Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topical anesthetic with vibration
Number of subjects: 61
Study: 7532319

Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg/day
Number of subjects: 0
Study: 3035913

Group type: EXPERIMENTAL
Intervention: Platinum (60 mg/m2), doxorubicin (40 mg/m2), and VP-16 (150 mg/m2) (PAV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Platinum (60 mg/m2), 4'-epidoxorubicin (50 mg/m2), and VP-16 (150 mg/m2) (PEV)
Number of subjects: 44
Study: 31137026

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment
Number of subjects: 20
Study: 28875511

Group type: EXPERIMENTAL
Intervention: Extended brief intervention for alcohol misuse
Number of subjects: 0
Study: 26111544

Group type: EXPERIMENTAL
Intervention: Hydrocodone (HYD) 20 to 120 mg taken once daily, average daily dose 57 mg
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 24042367

Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice daily for 12 weeks
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 20929973

Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task performed by young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task performed by elderly adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic implicit sequence-learning task for both age groups
Number of subjects: 0
Study: 19636019

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy)
Number of subjects: 285
Study: 16757181

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15275781

Group type: COMPARATOR
Intervention: Electronic questionnaires (E)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Paper questionnaires (P)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Comparison of mean difference scores between E and P
Number of subjects: 189

Group type: COMPARATOR
Intervention: Anxiety and experience scores
Number of subjects: 189
Study: 11736883

Group type: EXPERIMENTAL
Intervention: Finrozole 3 mg tablets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Finrozole 9 mg tablets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Finrozole 30 mg tablets
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Finrozole solution (dosage not specified)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Finrozole tablets (general)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Finrozole 3 mg tablets vs 9 mg tablets
Number of subjects: 23
Study: 9348763

Group type: EXPERIMENTAL
Intervention: Global interventions addressing risk factors for loss of mobility and functional decline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management
Number of subjects: 0
Study: 8501458

Group type: EXPERIMENTAL
Intervention: Enhanced education condition (slide-lecture show about kidney diseases and treatment)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard education condition (routine educational procedures at the hospital)
Number of subjects: 204
Study: 3442182

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10
Study: 30045307

Group type: EXPERIMENTAL
Intervention: Yellow yeast rice (1 pouch containing monacolin K) twice daily for 8 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 weeks)
Number of subjects: 68
Study: 27330183

Group type: EXPERIMENTAL
Intervention: Being observed by an ingroup member
Number of subjects: 0

Group type: COMPARATOR
Intervention: Being observed by an outgroup member
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with greater intergroup bias
Number of subjects: 0
Study: 26162648

Group type: EXPERIMENTAL
Intervention: Titrated physical activity intervention (n = 58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Online health education course (n = 58)
Number of subjects: 116
Study: 23973688

Group type: COMPARATOR
Intervention: simvastatin plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: simvastatin plus extended-release niacin (ERN, 1,500 to 2,000 mg/day)
Number of subjects: 0
Study: 21079438

Group type: EXPERIMENTAL
Intervention: New off-the-shelf insert
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motion-control shoe
Number of subjects: 15

Group type: COMPARATOR
Intervention: Existing off-the-shelf insert
Number of subjects: 15
Study: 17308269

Group type: EXPERIMENTAL
Intervention: AC (doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 IV every 3 weeks for six cycles)
Number of subjects: 3176

Group type: COMPARATOR
Intervention: A -> C (doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles)
Number of subjects: 3176

Group type: EXPERIMENTAL
Intervention: A -> C
Number of subjects: 3176

Group type: COMPARATOR
Intervention: AC
Number of subjects: 3176
Study: 14770192

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 11700811

Group type: EXPERIMENTAL
Intervention: Letter-only intervention (5 hospitals)
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Letter+visit intervention (5 hospitals)
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1117
Study: 9741602

Group type: EXPERIMENTAL
Intervention: Phonophoresis (PH) with 0.05% fluocinonide gel
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ultrasound (US) alone with an identical gel absent the steroid
Number of subjects: 49
Study: 7528288

Group type: EXPERIMENTAL
Intervention: Enterosgel application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepar
Number of subjects: 0
Study: 3182440

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30763939

Group type: COMPARATOR
Intervention: Raspberry supplementation (acute phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four-week daily raspberry supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 0
Study: 30573476

Group type: EXPERIMENTAL
Intervention: Management based on office blood pressure measurement (OBPM)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Management based on ambulatory blood pressure measurement (ABPM)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Management based on ABPM
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Management based on OBPM
Number of subjects: 1240
Study: 27131926

Group type: EXPERIMENTAL
Intervention: Covered Stents (CS)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 125
Study: 25159818

Group type: EXPERIMENTAL
Intervention: HDACi 109 (RG2833) at doses ranging from 30mg/day to 240mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDACi 109 (RG2833)
Number of subjects: 0
Study: 22023516

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous stem cell transplantation
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Complex karyotype, translocation t(4;14), gain of 1q21
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Complex karyotype and translocation t(4;14)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Normal karyotype or karyotype with ≤ 2 chromosomal changes
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Complex karyotype, translocation t(4;14), β(2)-microglobulin level > 2.5 mg/L
Number of subjects: 207
Study: 20952767

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo (for rosuvastatin)
Number of subjects: 608
Study: 17895943

Group type: EXPERIMENTAL
Intervention: Insulin infusion therapy
Number of subjects: 0
Study: 16762371

Group type: EXPERIMENTAL
Intervention: Risperidone (up to 6 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olanzapine (up to 15 mg)
Number of subjects: 36
Study: 12811263

Group type: EXPERIMENTAL
Intervention: rhBMP‐2 with CORNERSTONE‐SR Allograft Ring and ATLANTIS anterior cervical plate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cancellous iliac crest autograft with CORNERSTONE‐SR Allograft Ring and ATLANTIS anterior cervical plate
Number of subjects: 33
Study: 10227322

Group type: EXPERIMENTAL
Intervention: Outer-membrane protein (OMP) meningococcal vaccine
Number of subjects: 543
Study: 8921053

Group type: EXPERIMENTAL
Intervention: Purified follicle stimulating hormone (FSH, Metrodin High Purity) administered either i.m. (MHPim) or s.c. (MHPsc)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophins (HMGim, Pergonal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean circulating concentrations of LH in the follicular phase
Number of subjects: 60
Study: 1862890

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diamorphine
Number of subjects: 40
Study: 6638856

Group type: EXPERIMENTAL
Intervention: Cephradine prophylaxis (1 gram at induction of anaesthesia, followed by three postoperative doses of 1 gram at 6 hourly intervals)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no cephradine prophylaxis)
Number of subjects: 35
Study: 30705033

Group type: EXPERIMENTAL
Intervention: Aggressive dose escalation (group B)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard dose escalation (group A)
Number of subjects: 245
Study: 29268719

Group type: EXPERIMENTAL
Intervention: Structured dietary intervention delivered by primary care nurses with visits at baseline, 2-3 weeks, 3 months, and 6 months.
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 157
Study: 26031344

Group type: EXPERIMENTAL
Intervention: Face-to-face intensive training programme
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Face-to-face intensive training programme and an educational video
Number of subjects: 390

Group type: COMPARATOR
Intervention: Continuous nursing education
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study: 26265275

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 3635
Study: 21359834

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 462

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Rosiglitazone and Glipizide
Number of subjects: 462
Study: 19240522

Group type: EXPERIMENTAL
Intervention: Intraarticular sodium hyaluronate injections at weekly intervals for 3 weeks
Number of subjects: 33
Study: 17637266

Group type: EXPERIMENTAL
Intervention: Octreotide 50 microg/h for 72 h (Group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Octreotide 25 microg/h for 72 h (Group B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of Group A and Group B
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PFV(max) and PFV(mean)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HAV(max) and HAV(min)
Number of subjects: 26
Study: 14699268

Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 124

Group type: COMPARATOR
Intervention: Lumbar fusion
Number of subjects: 124
Study: 12580357

Group type: EXPERIMENTAL
Intervention: Xylitol (X)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sorbitol (S)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of xylitol and erythritol (XE)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of sorbitol and erythritol (SE)
Number of subjects: 98
Study: 10579376

Group type: EXPERIMENTAL
Intervention: 10,000 lux bright white light
Number of subjects: 34

Group type: COMPARATOR
Intervention: 50 lux dim red light (placebo control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34